fashion -WSS

fashion

author：fashion 2025-08-12 09:10:11 - browse：16559

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： The Readout: Lenmeldy, GLP

hotspot

WSS

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Will generative AI in health care meet the fate of IBM's Dr. Watson?

The stock market has soared this year, but will it last? Experts weigh in

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Why the world’s most expensive drug might be worth the price

Delta passengers in Vegas fall sick while waiting on flight in triple

explore

fashion

focus

As demand for Covid shots wanes, Moderna seeks its next success

Judge denies Trump's request for new trial in E. Jean Carroll case

Walensky prepares to leave CDC — and Congress — behind

Vertex Pharmaceuticals may move headquarters in Boston

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

As demand for Covid shots wanes, Moderna seeks its next success

Abortion pill case raises question: who can sue the FDA?

Bright Health sells Medicare Advantage business to Molina

Hormonal contraceptives don’t actually treat endometriosis

hotspot

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

After a decade, new Gardasil ad campaign gets it (mostly) right

Eliminate the waiting period for sterilization covered by Medicaid

Study says nonprofit hospitals fall short in charity care spending

Primary care physicians play key roles in Alzheimer's management

There’s a way to spot data fakery. All journals should be using it

leisure time

focus

hotspot

Wikipedia